Flow Neuroscience tDCS shows positive MINDFUL-1 interim analysis — trial continues to completion
Summary
Flow Neuroscience announced that an independent data monitoring committee reviewed the MINDFUL-1 pivotal trial interim analysis and recommended the trial continue to its pre-specified endpoint without modification, citing positive benefit-risk profile. While specific data was not disclosed, continuation without modification is generally interpreted as a positive interim signal.
Why it matters
Positive DMC interim review language is the closest thing to a public positive signal a blinded trial can produce. Investors and clinicians following the MINDFUL-1 readout for tDCS in TRD should interpret trial continuation without modification as meaningfully encouraging for the primary endpoint.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial